Hypofractionation for prostate cancer: a word of caution

Alberto Bossi; Pierre Blanchard

doi:10.1016/S1470-2045(15)00626-9

Hypofractionation for prostate cancer: a word of caution

Alberto Bossi, Pierre Blanchard

Résultats de recherche: Contribution à un journal › !!Comment/debate

3 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	406-407
Nombre de pages	2
journal	The Lancet Oncology
Volume	17
Numéro de publication	4
Les DOIs	https://doi.org/10.1016/S1470-2045(15)00626-9
état	Publié - 1 avr. 2016

Accès au document

10.1016/S1470-2045(15)00626-9

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{508afef4e81649528dbf03350cc6f281,

title = "Hypofractionation for prostate cancer: a word of caution",

author = "Alberto Bossi and Pierre Blanchard",

note = "Funding Information: AB reports grants and personal fees from Astellas Pharma, Ipsen Pharma, and Sanofi Aventis, and non-financial support from Elekta, outside the submitted work; PB reports grants from Astellas Pharma and personal fees from Sanofi Aventis, outside the submitted work.",

year = "2016",

month = apr,

day = "1",

doi = "10.1016/S1470-2045(15)00626-9",

language = "English",

volume = "17",

pages = "406--407",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "4",

}

TY - JOUR

T1 - Hypofractionation for prostate cancer

T2 - a word of caution

AU - Bossi, Alberto

AU - Blanchard, Pierre

N1 - Funding Information: AB reports grants and personal fees from Astellas Pharma, Ipsen Pharma, and Sanofi Aventis, and non-financial support from Elekta, outside the submitted work; PB reports grants from Astellas Pharma and personal fees from Sanofi Aventis, outside the submitted work.

PY - 2016/4/1

Y1 - 2016/4/1

UR - http://www.scopus.com/inward/record.url?scp=84959925807&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(15)00626-9

DO - 10.1016/S1470-2045(15)00626-9

M3 - Comment/debate

C2 - 26968358

AN - SCOPUS:84959925807

SN - 1470-2045

VL - 17

SP - 406

EP - 407

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 4

ER -